This weekend President Trump touted the newly authorized use of convalescent plasma for treating COVID-19. However, the data is mixed—and experts aren’t totally sold on the powers of this type of therapy.
Over the weekend, the Food and Drug Administration (FDA) gave convalescent plasma therapy an emergency use authorization to treat COVID-19. After reviewing the existing data on COVID-19 and plasma therapy, the FDA concluded that “this product may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product.” In particular, the agency determined that it’s “reasonable to believe” that using convalescent plasma to treat COVID-19 may reduce the severity or length of the illness.
Unlike a normal drug approval that typically comes after years of extensive testing (including randomized controlled clinical trials), this type of authorization is reserved for emergency situations when there may not be time or resources to conduct full trials on a treatment that appears promising—especially when there aren’t any approved alternatives, the FDA explains.
The authorization is intriguing considering that, just last week, the FDA held off on its decision after health experts including Anthony Fauci, M.D., head of the National Institute of Allergy and Infectious Diseases, intervened because they felt the current data on plasma therapy was not strong enough to warrant an emergency use authorization, the New York Times reports. It’s not clear exactly what lead to the weekend’s change, but other experts are still cautious about drawing any conclusions from the current research.
So what exactly is convalescent plasma therapy? It’s a type of antibody treatment that relies on collecting those precious antibodies from people who have recovered from COVID-19. Then the plasma containing the antibodies (again, collected from the blood of people who’ve recovered from the infection) is administered to patients who currently have the infection. The idea is that the antibodies in the plasma will help the patient’s body fight the infection since they don’t yet have enough antibodies to do so on their own.
If this idea sounds familiar, that’s probably because it’s been investigated in previous outbreaks, including the 2014 ebola outbreak, the 2009 H1N1 pandemic, as well as outbreaks of MERS. And it’s been used on an experimental basis in the current coronavirus pandemic for months now. (Over 70,000 patients have received convalescent plasma via the Mayo Clinic’s program since April, the FDA says.) But the new FDA authorization provides a more comprehensive understanding about the effectiveness of this particular type of therapy.
In one recent preprint study (meaning it has not been peer-reviewed), researchers looked at data from more than 35,000 COVID-19 patients at 2,807 medical facilities across the country who received convalescent plasma therapy through the Mayo Clinic’s expanded access program. Because everyone in the study got the plasma therapy, there was no control group. However, those patients who received the therapy within three days of being diagnosed showed a lower mortality rate compared to those who received it four or more days after being diagnosed.
Specifically, the mortality rate for the early plasma therapy group was 8.7% (1,340 deaths out of 15,407 participants) at seven days and 21.6% (3,329 deaths) at 30 days. For the later group, the mortality rate was 11.9% (2,366 out of 19,15 participants) at seven days and 26.7% (5,323 deaths) at 30 days. Those who received plasma containing higher levels of IgG antibodies also showed significantly lower mortality rates.
These results suggest that convalescent plasma therapy can be somewhat helpful in keeping patients alive, especially if they receive it earlier on in their disease course. However, since there’s no control group here, it’s difficult to really know how much of these results is due to the therapy.